China Aiming To Slash Certain Cancer Drug Prices To Ease Access
This article was originally published in PharmAsia News
Executive Summary
Amid calls to expand access to costly patented cancer drugs, China is negotiating with several suppliers for the potential inclusion of selected targeted therapies in national reimbursement schemes. But could the potential benefits justify the likely 50% cuts?
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.